Objective: To determine whether perinatal outcomes are influenced by the in
terval between antenatal betamethasone administration and delivery.
Methods: We did a retrospective cohort analysis of liveborn singleton neona
tes born between 28 and 34 weeks' gestation after a single course of betame
thasone, defined as two 12-mg doses over 24 hours. Subjects were grouped ac
cording to length of interval between initial betamethasone dose and delive
ry (1-2 days, 3-7 days, and 8-14 days). We excluded women who had membranes
ruptured for longer than 24 hours before delivery, delivery before the sec
ond dose of betamethasone, or more than two doses of betamethasone. Data we
re analyzed by Student t test, chi (2) test, or Fisher exact test. Multiple
logistic regression analyses were done using suspected risk factors for re
spiratory distress syndrome (RDS) and intraventricular hemorrhage (IVH). We
calculated that a sample of 200 women would provide more than 80% power to
detect a 50% reduction in incidence of RDS for a two-sided test of signifi
cance at a critical level of .05.
Results: Among 216 women, 97 delivered in 1-2 days, 78 in 3-7 days, and 41
in 8-14 days after a single course of betamethasone. Groups were similar in
selected demographics, tocolytic exposure, gestational age at delivery, mo
des of delivery, and mean birth weights. There were no significant differen
ces in frequencies of RDS (39.2%, 41.1%, and 36.6%, respectively) or grades
3-4 IVH (1.1%, 1.3%, and 0%, respectively) between groups. Frequencies of
selected perinatal infectious outcomes also were similar between groups. Mu
ltiple logistic regression analyses found no association between RDS or IVH
and delivery more than 7 days from betamethasone therapy.
Conclusion: There were no differences in perinatal out comes in pregnancies
delivered 8-14 days after antenatal exposure to betamethasone compared wit
h those delivered within 7 days of exposure. (C) 2001 by The American Colle
ge of Obstetricians and Gynecologists.